Diagnostic Firm Biofield Looks To Broaden Scope in China and India
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Looking to penetrate deeper into the Asian market, diagnostic equipment distributor Biofield, owned by Hong Kong-based MacKay Holdings, has acquired new cancer diagnostic products which it plans to market in China and India. Last week, the company announced it had acquired worldwide distribution rights for various cancer diagnostic products from ValiRx, a UK-based biotechnology company that focuses on cancer products
You may also be interested in...
MacKay Group Chairman James MacKay On Pursuing A “Starbucks” Model For Diagnostics In China: An Interview With PharmAsia News
Armed with a stable of non-invasive diagnostic technologies, the MacKay Group plans to capitalize on the growing need across Asia for inexpensive diagnostic equipment. Last month, the company acquired new cervical cancer diagnostic products through its Biofield unit to complement its own breast cancer diagnostic products, which sell for less than $20,000 (PharmAsia News, Feb. 12, 2009). MacKay Group Chairman James MacKay spoke to PharmAsia News' Hong Kong bureau to outline his vision for a "Starbucks approach" to health care, one in which cancer screenings go alongside facials and manicures at a nearby beauty salon. That reality, he says, is just around the corner.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).